Montelukast Sodium

• A clinical trial to evaluate the efficacy and safety of a mixture of allergenic extracts of D. pteronyssinus and D. farinae, in patients suf… Pending
  2025-521230-29-00 Phase III 1 country LETI Pharma S.L.U.
• Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease, an open-label, phase II extension trial (MONTPARK_OLE) Pending
  2026-525906-37-00 Phase III 1 country Karolinska University Hospital
• Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease (MONTPARK), a double-blind randomized placebo-controlled pha… Recruiting
  2023-504278-39-00 Phase II 1 country Karolinska University Hospital
• Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone… Ended
  2023-508310-41-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab Ended
  2023-507180-19-00 Phase II 7 countries Sanofi-Aventis Recherche & Developpement
• A study to investigate subcutaneous isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or … Ended
  2023-508870-27-00 Phase II 3 countries Sanofi-Aventis Recherche & Developpement
• SC versus IV isatuximab in combination with pomalidomide and dexamethasone in RRMM Ended
  2023-508869-32-00 Phase III 10 countries Sanofi-Aventis Recherche & Developpement
• Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma Ended
  2023-507419-37-00 Phase III 11 countries Sanofi-Aventis Recherche & Developpement
• Evaluation of Amivantamab Infusion Related Reaction Mitigation Ended
  2023-506578-11-00 Phase II 2 countries Janssen - Cilag International

Showing 1–9 of 9 trials